Drug intelligence / Profile preview

snx-5422

Development stage: Phase 2
Lead developer: Esanex
Modality: Small Molecules
Administration: Oral

Overview

SNX-5422 is a synthetic small molecule inhibitor of heat shock protein 90 (Hsp90), developed as an orally bioavailable prodrug of SNX-2112. It demonstrates strong efficacy and tolerability in preclinical models and has been investigated for its potential antineoplastic activity across a broad range of human cancer cell lines. The drug causes degradation of important Hsp90 client proteins and exhibits potent antiproliferative effects in various cancer types.

Other names: 908115-27-5BF52J69Q8TBF-52J69Q8TBF 52J69Q8TDTXSID50238270DTXSID-50238270DTXSID 50238270Glycine, trans-4-((2-(aminocarbonyl)-5-(4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl)phenyl)amino)cyclohexyl ester

Targets

HSP90 (Heat shock protein 90 chaperone complex)TRAP1 (Tumor necrosis factor receptor-associated protein 1)HSP90B1 (GRP94)

Beyond the preview

Go deeper on snx-5422.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on snx-5422.

Explore the full profile